Abstract Number: 0035 • ACR Convergence 2026
Novel cytokine candidate, p40-EBI3 complex regulates profibrotic T cell and B cell and inhibits systemic sclerosis via simultaneous regulation of STAT3/STAT5 signals
Background/Purpose: The interleukin (IL)-12 cytokine family regulate immune cells in several autoimmune diseases. In a previous study, we confirmed that p40-EBI3 naturally exists in vivo…Abstract Number: 0741 • ACR Convergence 2026
Immune Checkpoint Inhibitor-induced Raynaud’s Phenomenon: A Descriptive Cohort Study with Cytokine Characterization
Background/Purpose: Immune checkpoint inhibitor (ICI)-induced Raynaud's phenomenon (RP) is a rare and possibly underrecognized rheumatological immune related adverse event (irAE). RP secondary to autoimmune rheumatic…Abstract Number: 1960 • ACR Convergence 2026
Amplification of the Th17/IL-17 Pathway Activation Marks the Transition from Very Early Systemic Sclerosis (VEDOSS) to Established Systemic Sclerosis: A Multi-Omics Analysis
Background/Purpose: Systemic sclerosis (SSc) carries the highest mortality among rheumatic diseases, underscoring the need to identify immunological drivers before irreversible organ damage occurs. The Very…Abstract Number: 2868 • ACR Convergence 2026
Distinct Plasma Cytokine Profiles Across Rheumatic Diseases Reveal an RA-Specific Interstitial Lung Disease Signature
Background/Purpose: Systemic autoimmune rheumatic diseases (SARDs) cause significant morbidity and mortality through diverse mechanisms. Major implicated drivers include interferon (IFN), T cell, inflammasome/IL-6, and TNF-α…Abstract Number: 0057 • ACR Convergence 2026
Clinical Correlates of Anti-cytokine Antibodies in Patients with Systemic Lupus Erythematosus
Background/Purpose: Anti-cytokine antibodies (ACAs) are a group of autoantibodies that target interleukins, interferons, and other cytokine subgroups. ACAs are enriched in autoimmune diseases such as…Abstract Number: 0884 • ACR Convergence 2026
Age-Associated B cells Exacerbate Primary Sjögren Disease by Promoting Follicular T Helper Cell Differentiation Through PD-L1
Background/Purpose: Primary Sjögren disease (SjD) is a systemic autoimmune disease characterized by exocrine gland dysfunction and B cell overactivation. However, the role of age-associated B…Abstract Number: 1968 • ACR Convergence 2026
Nicotinamide Deficiency Impairs NAD⁺ Synthesis and Drives Fibrosis
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease associated with high mortality. Its hallmark feature is fibrosis, which affects the skin, lungs, and various organs.…Abstract Number: 2936 • ACR Convergence 2026
Beyond Seven Days: Ferritin Kinetics in Adult ICU Hemophagocytic Lymphohistiocytosis
Background/Purpose: Ferritin is central to hemophagocytic lymphohistiocytosis (HLH) diagnosis and monitoring, but adult ferritin trajectories beyond the acute phase remain poorly characterized. Most literature reports…Abstract Number: 0063 • ACR Convergence 2026
Per- and Polyfluouralkyl Substances (PFAS) Correlate with and Improve the Ability of Select Immune Biomarkers to Differentiate Stage 2 (Pre-classification) SLE vs. Unaffected Lupus Relatives in a Nested Study of the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort
Background/Purpose: Per- and polyfluoroalkyl substances (PFAS) are synthetic chemicals made of carbon-fluorine bonds that do not decay. Used in a variety of consumer products, PFAS…Abstract Number: 0966 • ACR Convergence 2026
AI-Enabled Discovery of Small-Molecule Inhibitors Targeting the TNF Superfamily
Background/Purpose: TNF superfamily (TNFSF) ligand-receptor axes are central mediators of autoimmune inflammation, yet therapeutic modulation has been restricted to injectable biologics. Previously disclosed oral TNF-α…Abstract Number: 1975 • ACR Convergence 2026
T1 IFN Activity In Systemic Sclerosis Is A Molecular Endotype With Asymmetric Temporal Variability: Results From A Longitudinal Cohort
Background/Purpose: Type I interferon (T1 IFN) pathway activation is a central pathogenic mechanism in systemic sclerosis (SSc) and has emerged as a useful biomarker for…Abstract Number: 2943 • ACR Convergence 2026
Biomarker-Driven Insights From the Phase 2a AFFINITY Study Evaluating Guselkumab + Golimumab Combination Therapy Versus Guselkumab Monotherapy in Psoriatic Arthritis
Background/Purpose: Phase 2a, randomized, double-blind, active-controlled, proof-of-concept AFFINITY study (NCT05071664) evaluated guselkumab (GUS) + golimumab (GOL) combination therapy (CT) vs GUS monotherapy (MT) in adult…Abstract Number: 0078 • ACR Convergence 2026
3D Patient-Derived Synovial Organoids (Synovioids): From Biopsy to Personalized Drug Selection in Rheumatoid Arthritis
Background/Purpose: RA exhibits significant heterogeneity in disease mechanisms and therapeutic responses, with 30-40% treatment failure rates. Traditional 2D models lack cellular complexity and fail to accurately predict individual…Abstract Number: 0975 • ACR Convergence 2026
TJ-TL23: A Novel Long Half-Life Bispecific Antibody Simultaneously Neutralizing TL1A and IL-23 for Autoimmune Diseases via Synergistic Anti-Inflammation and Anti-Fibrosis
Background/Purpose: IL-23 drives Th17-related inflammation with proven clinical value in autoimmune diseases, while tumor necrosis factor-like cytokine 1A (TL1A), a mucosal immune amplifier, exacerbates inflammation…Abstract Number: 1977 • ACR Convergence 2026
A Pro-Migratory Paradox: Methylprednisolone Dampens Cytokine Secretion yet Enhances Neutrophil Migration in Health and Systemic Lupus Erythematosus
Background/Purpose: Neutrophils are increasingly recognized as drivers of systemic lupus erythematosus (SLE), and glucocorticoids such as methylprednisolone (MP) are widely used to suppress inflammation. While…
ACR Meeting Abstracts